A C-peptide blood test measures how much insulin your pancreas is making. It is most often used when diabetes type is unclear, when insulin production needs to be checked, or when a person has unexplained low blood sugar. C-peptide rises and falls with your own insulin because both are released from the same proinsulin molecule. Unlike injected insulin, C-peptide is not found in insulin medication, so it helps show the body’s natural insulin output even when someone uses insulin shots or a pump.
A normal C-peptide result usually means the pancreas is still making insulin, but the result only makes sense with the blood glucose level taken at the same time. A low result during high glucose suggests poor insulin production. A high result often points toward insulin resistance, but kidney function, medicines, and recent food intake can also affect the number.
- C-peptide shows how much insulin your pancreas is making, not how much insulin you injected.
- A common fasting adult reference range is roughly 0.5–2.0 ng/mL, but many labs use wider ranges such as about 0.8–3.8 ng/mL.
- Low C-peptide with high glucose suggests reduced beta-cell insulin production, often seen in type 1 diabetes, LADA, or advanced diabetes.
- High C-peptide with high glucose often means insulin resistance, because the pancreas is making extra insulin to overcome reduced insulin sensitivity.
- C-peptide should usually be interpreted with a same-sample glucose result, kidney function, medication history, and whether the test was fasting or stimulated.
Table of Contents
- What C-Peptide Measures
- C-Peptide Normal Range
- High C-Peptide Results
- Low C-Peptide Results
- Fasting, Random, and Stimulated Testing
- Diabetes Type and Insulin Production
- Test Preparation and Accuracy
- Follow-Up After an Abnormal Result
What C-Peptide Measures
C-peptide is a small protein fragment released when the pancreas makes insulin. Inside pancreatic beta cells, insulin starts as a larger molecule called proinsulin. When proinsulin is split, it forms insulin and C-peptide in roughly equal amounts. Insulin helps move glucose from the blood into cells. C-peptide does not lower glucose in the same direct way, but it is a useful marker of the body’s own insulin production.
This is why C-peptide is different from an insulin blood test. Insulin levels can reflect both natural insulin and, in some testing situations, injected insulin or insulin antibodies. C-peptide mainly reflects insulin made by the pancreas. Most insulin medications do not contain C-peptide.
Doctors use C-peptide to answer questions such as:
- Is the pancreas still making enough insulin?
- Does a person with diabetes have severe insulin deficiency?
- Is high glucose more likely from insulin resistance or from low insulin production?
- Is low blood sugar caused by too much natural insulin, an insulin-producing tumor, certain diabetes medicines, or injected insulin?
- Could the diabetes pattern fit type 1 diabetes, type 2 diabetes, latent autoimmune diabetes in adults, or another form?
C-peptide is not a general “metabolic health score.” A result can look normal even when glucose control is poor. For example, a person with type 2 diabetes may have a normal or high C-peptide level because the pancreas is working hard to overcome insulin resistance. Another person may have a normal fasting C-peptide but a weak response after a meal. The number matters most when it is matched to the glucose level and the clinical situation.
C-Peptide Normal Range
A common fasting C-peptide reference range for adults is roughly 0.5–2.0 ng/mL, which is about 0.17–0.66 nmol/L. Some laboratories use wider fasting reference ranges, often around 0.8–3.8 ng/mL or similar. The exact normal range depends on the lab method, sample type, fasting status, and population used to create the reference interval.
Use the reference range printed on your own lab report first. C-peptide assays are not perfectly interchangeable across laboratories. A value that is just above or below one lab’s range may fall inside another lab’s range.
| Pattern | Common meaning | Important context |
|---|---|---|
| Low C-peptide with high glucose | The pancreas is not making enough insulin for the glucose level | Seen in type 1 diabetes, LADA, advanced beta-cell failure, or pancreatic disease |
| Normal C-peptide with normal glucose | Insulin production may be appropriate | Does not rule out early diabetes, insulin resistance, or abnormal after-meal glucose |
| High C-peptide with high glucose | The pancreas is making extra insulin, often because of insulin resistance | Common in type 2 diabetes, obesity-related insulin resistance, steroid use, or early metabolic disease |
| High C-peptide with low glucose | Too much natural insulin may be present | Can occur with insulinoma or sulfonylurea/meglitinide medications and needs careful evaluation |
| Low C-peptide with low glucose | Insulin production is appropriately suppressed, or pancreatic output is very low | Can help separate injected insulin exposure from natural insulin excess in selected cases |
C-peptide is often reported in either ng/mL or nmol/L. To convert approximately:
- ng/mL × 0.331 = nmol/L
- nmol/L × 3.02 = ng/mL
For example, a C-peptide of 1.0 ng/mL is about 0.33 nmol/L. A C-peptide of 0.2 nmol/L is about 0.6 ng/mL.
A normal result does not always mean “no problem.” If glucose is high, a normal C-peptide may actually be too low for the situation, because the pancreas should usually increase insulin output when glucose rises. If glucose is low, a normal C-peptide may be too high, because insulin production should normally turn down during hypoglycemia.
High C-Peptide Results
High C-peptide usually means the pancreas is releasing more insulin than usual. The most common reason is insulin resistance. In insulin resistance, muscle, liver, and fat cells do not respond to insulin as well as expected. The pancreas compensates by making more insulin, and C-peptide rises along with it.
High C-peptide is often seen with:
- Type 2 diabetes, especially early or middle stages
- Prediabetes with insulin resistance
- Higher body weight or increased visceral fat
- Polycystic ovary syndrome, when insulin resistance is present
- Metabolic syndrome
- Steroid medicines, some antipsychotic medicines, or other drugs that raise glucose
- Kidney disease, because the kidneys help clear C-peptide from the blood
- Insulinoma or other causes of inappropriate insulin secretion, especially when glucose is low
A high result is not interpreted the same way in every glucose pattern. High C-peptide with high glucose usually means the pancreas is trying to keep up but cannot overcome insulin resistance enough to normalize glucose. In that situation, related markers such as fasting glucose, A1c, triglycerides, HDL cholesterol, waist size, and blood pressure may help show the broader metabolic pattern. A person comparing glucose and insulin-related markers may also benefit from understanding fasting glucose and fasting insulin together.
High C-peptide with low glucose is a different issue. During true hypoglycemia, the pancreas should reduce insulin release. If C-peptide stays high while glucose is low, clinicians may look for causes of excess natural insulin, including sulfonylurea or meglitinide medication exposure and, less commonly, insulinoma. In that setting, testing often includes glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and a sulfonylurea screen drawn during the low-glucose episode.
Kidney function can make C-peptide look higher than expected. C-peptide is cleared partly through the kidneys, so chronic kidney disease can raise levels even if insulin production has not increased. This is one reason C-peptide should be read alongside creatinine and estimated glomerular filtration rate when kidney disease is known or suspected.
Low C-Peptide Results
Low C-peptide means the pancreas is making little insulin. The meaning depends strongly on the glucose level. Low C-peptide during high blood glucose is more concerning than low C-peptide during fasting low-normal glucose.
Low C-peptide can occur with:
- Type 1 diabetes
- Latent autoimmune diabetes in adults, often called LADA
- Long-standing type 2 diabetes with beta-cell exhaustion
- Pancreatic surgery or pancreatic disease
- Severe pancreatitis or chronic pancreatic damage
- Advanced cystic fibrosis-related diabetes
- Prolonged very low carbohydrate intake or fasting, when glucose and insulin demand are low
- Injected insulin use, which can suppress the body’s own insulin release
A very low C-peptide in a person with diabetes suggests limited insulin reserve. This can mean a higher risk of large glucose swings, ketone production during illness or missed insulin, and greater need for insulin therapy. It may also explain why oral diabetes medicines that depend on beta-cell function do not work well.
Low C-peptide is especially important when paired with symptoms or lab results suggesting insulin deficiency: unintended weight loss, frequent urination, excessive thirst, high glucose, ketones, or a history of diabetic ketoacidosis. People with high glucose and ketones should not wait for routine follow-up, because diabetic ketoacidosis can become dangerous quickly. A separate pattern involving high glucose and high ketones needs urgent clinical attention.
Some clinicians use C-peptide thresholds to estimate insulin reserve. Values below about 0.2 nmol/L are often treated as evidence of severe insulin deficiency, especially when glucose is high or after stimulation. Values above about 0.6 nmol/L usually suggest meaningful insulin production. Values between those points are a gray zone and should be interpreted with glucose, timing, antibodies, body weight, medications, and diabetes duration.
Fasting, Random, and Stimulated Testing
C-peptide can be measured fasting, randomly, or after stimulation. These are not identical tests.
A fasting C-peptide is usually drawn after 8–12 hours without calories. It shows baseline insulin production. This is the most common form of testing, but it can underestimate the pancreas’s ability to respond after food.
A random C-peptide is drawn without strict fasting. It can be useful if the same blood draw also includes glucose. A random result is easier to interpret when glucose is clearly elevated, because the pancreas should be producing insulin in response.
A stimulated C-peptide measures the beta-cell response after a stimulus. The stimulus may be a mixed meal, oral glucose, or glucagon injection, depending on the clinical protocol. Stimulated testing can show whether the pancreas still has reserve even when fasting output is modest.
| Test type | How it is done | Why it may be used |
|---|---|---|
| Fasting C-peptide | Blood draw after an overnight fast | Baseline insulin production, diabetes classification, insulin reserve |
| Random C-peptide | Blood draw without fasting, ideally with same-sample glucose | Practical estimate of insulin production during usual conditions |
| Mixed-meal stimulated C-peptide | Blood draws after a standardized meal drink | Beta-cell response after food; often used in research and specialty care |
| Glucagon-stimulated C-peptide | Blood draws before and after glucagon injection | Pancreatic insulin reserve when a controlled stimulus is needed |
The same C-peptide value can mean different things at different glucose levels. A C-peptide of 1.0 ng/mL may be reasonable if glucose is 85 mg/dL. It may be inadequate if glucose is 300 mg/dL, because the pancreas should usually be producing more insulin in response to that glucose level.
For this reason, C-peptide is strongest when paired with a glucose measurement from the same blood draw. If the goal is to understand diabetes status, clinicians often compare C-peptide with blood glucose test ranges, A1c, medication history, and symptoms rather than using C-peptide alone.
Diabetes Type and Insulin Production
C-peptide can help clarify diabetes type, but it does not replace the full clinical picture. Age, body weight, family history, antibody testing, ketones, insulin needs, and the speed of onset all matter.
In classic type 1 diabetes, the immune system damages pancreatic beta cells. C-peptide often becomes very low over time because the pancreas loses the ability to make insulin. However, some people with type 1 diabetes still make small amounts of C-peptide for years, especially near diagnosis or when using highly sensitive assays.
In type 2 diabetes, C-peptide is often normal or high at first. The body resists insulin’s effects, so the pancreas makes more insulin to compensate. Over years, beta cells may weaken, and C-peptide can fall. A person with long-standing type 2 diabetes may eventually have low insulin production and need insulin therapy, even if the original problem started as insulin resistance.
LADA can sit between the usual patterns. Adults with LADA may initially look like they have type 2 diabetes because they do not need insulin right away. Over time, autoimmune beta-cell loss progresses, and C-peptide often falls. Antibody testing, especially GAD antibodies and other islet autoantibodies, can help separate LADA from ordinary type 2 diabetes.
C-peptide is also useful when insulin and C-peptide appear to disagree. For example, high insulin with low C-peptide during hypoglycemia can suggest injected insulin exposure, because injected insulin raises insulin levels without raising C-peptide. High insulin with high C-peptide during hypoglycemia suggests the insulin is coming from inside the body or from a medicine that stimulates the pancreas.
For diabetes classification, C-peptide is often paired with antibody testing and glucose history. A person trying to understand the relationship between these two pancreatic markers may need a more detailed comparison of C-peptide and insulin. If the main question is glucose control over time, C-peptide is not a replacement for hemoglobin A1c, fasting glucose, or continuous glucose data.
Test Preparation and Accuracy
Preparation depends on the reason for the test. For many fasting C-peptide tests, you may be asked to avoid calories for 8–12 hours. Water is usually allowed. Do not stop insulin, diabetes medicines, or other prescribed drugs unless your clinician gives specific instructions.
Tell the ordering clinician and lab about:
- Insulin use, including injections, pumps, and recent dose changes
- Sulfonylureas or meglitinides, such as glipizide, glyburide, glimepiride, repaglinide, or nateglinide
- GLP-1 receptor agonists or dual incretin medicines
- Steroids or other medicines that raise glucose
- Kidney disease or reduced eGFR
- Pregnancy
- Recent severe illness, infection, surgery, or major stress
- Biotin supplements, if the lab uses an assay affected by biotin interference
Food intake can raise C-peptide. That is not a problem if the test is intentionally random or stimulated, but it can confuse a fasting interpretation. Recent hypoglycemia, heavy exercise, alcohol intake, or a very low carbohydrate diet can also lower insulin demand and reduce C-peptide.
Glucose level at the time of testing is one of the biggest accuracy issues. A low or normal C-peptide during low glucose may simply mean the pancreas is appropriately quiet. A low or normal C-peptide during high glucose is more concerning. For that reason, many clinicians order glucose with C-peptide rather than C-peptide alone.
Assay differences also matter. C-peptide tests use immunoassay methods, and results may vary by lab. When tracking changes over time, it is helpful to use the same laboratory when possible. Small changes near the reference limit may reflect lab variation rather than a true change in beta-cell function.
Follow-Up After an Abnormal Result
Follow-up depends on whether C-peptide is high, low, or mismatched with glucose.
If C-peptide is high and glucose is also high, the next step is often to evaluate insulin resistance and overall metabolic risk. That may include fasting glucose, A1c, fasting insulin, lipid panel, blood pressure, waist circumference, liver enzymes, and kidney function. Lifestyle treatment, weight management, sleep, physical activity, and medication choices may all be discussed depending on the person’s diabetes status and risk profile. If insulin resistance is the main concern, a HOMA-IR test may sometimes be used with fasting glucose and fasting insulin, though it is not required for every patient.
If C-peptide is low and glucose is high, follow-up may focus on insulin deficiency. Clinicians may check islet autoantibodies, ketones, A1c, and medication response. They may also review whether insulin therapy is needed or whether current insulin dosing is adequate. A person with symptoms of severe hyperglycemia, vomiting, abdominal pain, rapid breathing, confusion, or moderate-to-large ketones needs urgent medical care.
If C-peptide is high during low glucose, the workup is more specialized. The most useful labs are drawn during the low-glucose episode, not hours or days later. Clinicians may order insulin, C-peptide, proinsulin, beta-hydroxybutyrate, cortisol in selected cases, and a sulfonylurea/meglitinide screen. Imaging for insulinoma is usually considered only after blood tests show inappropriate natural insulin production.
If C-peptide is borderline, repeating the test under clearer conditions may help. A fasting repeat with same-sample glucose may answer one question, while stimulated testing may answer another. A borderline result in a newly diagnosed adult with diabetes may also lead to antibody testing, especially if the person is lean, has rapid worsening of glucose, has ketones, or has a personal or family history of autoimmune disease.
C-peptide is most useful when it changes a decision. It may help decide whether diabetes therapy should focus mainly on insulin resistance, insulin replacement, further diagnostic testing, or evaluation for unexplained hypoglycemia. It is less useful as a stand-alone wellness marker or as a single number to optimize without a clear medical question.
References
- A Practical Review of C-Peptide Testing in Diabetes 2017 (Review)
- The clinical utility of C-peptide measurement in the care of patients with diabetes 2013 (Review)
- Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications 2021
- Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT) 2021
- The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) 2021
- 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025 2025 (Guideline)
Disclaimer
C-peptide results should be interpreted by a qualified clinician using the lab’s own reference range, the glucose level drawn at the same time, medication history, kidney function, and the reason for testing. Seek urgent medical care for high glucose with ketones, vomiting, confusion, severe weakness, or symptoms of severe low blood sugar.
